BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome

[GlobeNewswire] – SAN RAFAEL, Calif. — BioMarin Pharmaceutical Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for … more

View todays social media effects on BMRN

View the latest stocks trending across Twitter. Click to view dashboard

See who BioMarin is hiring next, click here to view